Evidence
Alzheimers Dement. 2024 Jun 14. doi: 10.1002/alz.13902. Online ahead of print.
ABSTRACT
BACKGROUND: The mechanisms linking mild behavioral impairment (MBI) and Alzheimer’s disease (AD) have been insufficiently explored, with conflicting results regarding tau protein and few data on other metabolic markers. We aimed to evaluate the longitudinal association of the MBI domains and a spectrum of plasma biomarkers.
METHODS: Our study is a secondary analysis of data from NOLAN. The longitudinal association of the MBI domains with plasma biomarkers, including pTau181, was tested using adjusted linear mixed-effects models.
RESULTS: The sample comprised 359 participants (60% female, mean age: 78.3, standard deviation: 0.3 years). After 1 year, the MBI domain of abnormal perception was associated with steeper increases in plasma pTau181. Abnormal perception, decreased motivation, and impulse dyscontrol were associated with homocysteine or insulin dysregulation.
DISCUSSION: Apart from the association with plasma pTau181, our results suggest that MBI might also represent metabolic dysregulation, probably contributing to dementia transition among older adults with subjective cognitive decline or mild cognitive impairment.
HIGHLIGHTS: Mild behavioral impairment (MBI) psychosis was associated with steeper increases in plasma p. pTau could be a pharmacological target to treat agitation and psychosis symptoms. MBI domains were linked to metabolic dysregulation involving insulin and homocysteine.
PMID:38877658 | DOI:10.1002/alz.13902
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Mild behavioral impairment domains are longitudinally associated with pTAU and metabolic biomarkers in dementia-free older adults
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- The mind and motion: exploring the interplay between physical activity and Mild Behavioral Impairment in dementia-free older adults
- The effect of study partner characteristics on the reporting of neuropsychiatric symptoms across the neurocognitive spectrum
- Tau pathology mediate the plasma biomarkers and cognitive function in patients with mild cognitive impairment
- Unraveling the Potential Underlying Mechanisms of Mild Behavioral Impairment: Focusing on Amyloid and Tau Pathology
- Association of polygenic risk scores with Alzheimer's disease and plasma biomarkers among Chinese older adults: A community-based study
- Assessing cognitive impairment and disability in older adults through the lens of whole brain white matter patterns
- Assessing cognitive impairment and disability in older adults through the lens of whole brain white matter patterns
- CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease
- Impact of amyloid and cardiometabolic risk factors on prognostic capacity of plasma neurofilament light chain for neurodegeneration
- Novel measures of cognition and function for the AD spectrum in the Novel Measures for Alzheimer's Disease Prevention Trials (NoMAD) project: Psychometric properties, convergent validation, and contrasts with established measures
- Predicting the severity of mood and neuropsychiatric symptoms from digital biomarkers using wearable physiological data and deep learning
- The Alzheimer's Disease Neuroimaging Initiative Clinical Core
- Elevated plasma neurofilament light was associated with multi-modal neuroimaging features in Alzheimer's disease signature regions and predicted future tau deposition
- Psychosis in Alzheimer Disease and Elevations in Disease-Relevant Biomarkers
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
- Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment
- Diagnostic and predictive power of plasma proteins in Alzheimer's disease: a cross-sectional and longitudinal study in China
- Plasma Phosphorylated Tau 217 and Abeta42/40 to Predict Early Brain Abeta Accumulation in People Without Cognitive Impairment
- Plasma Phosphorylated Tau 217 and Abeta42/40 to Predict Early Brain Abeta Accumulation in People Without Cognitive Impairment
- Significance of plasma p-tau217 in predicting long-term dementia risk in older community residents: Insights from machine learning approaches
- Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive Decline
- Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia
- Loneliness, cerebrovascular and Alzheimer's disease pathology, and cognition
- Alzheimer's Association launches new journal on the impacts of behavioral, social, and economic factors on health and dementia care in aging
- Temporo-frontoparietal hypoconnectivity as a biomarker for isolated language impairment in mild cognitive impairment: A cross-cohort comparison
- The effectiveness of mindfulness-based intervention for psychological distress and emotion regulation in college students with non-suicidal self-injury
- Clonal hematopoiesis of indeterminate potential is associated with reduced risk of cognitive impairment in patients with chronic kidney disease
- Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals
- Storyteller in ADNI4: Application of an early Alzheimer's disease screening tool using brief, remote, and speech-based testing
- Correlates of Mild Behavioral Impairment in Older Adults: Protocol for a Scoping Review
- Correlates of Mild Behavioral Impairment in Older Adults: Protocol for a Scoping Review
- Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers
- Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers
- Cerebral glucose metabolism in Alzheimer's disease
- Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
- Assessing blood-brain barrier dysfunction and its association with Alzheimer's pathology, cognitive impairment and neuroinflammation
- Minding mentalizing - convergent validity of the Mentalization Breakdown Interview
- Identifying longitudinal cognitive resilience from cross-sectional amyloid, tau, and neurodegeneration
- Examining Associations Between Smartphone Use and Clinical Severity in Frontotemporal Dementia: Proof-of-Concept Study
- Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
- Cerebrospinal fluid p-tau181, 217, and 231 in definite Creutzfeldt-Jakob disease with and without concomitant pathologies
- Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies
- Plasma Biomarkers of Traumatic Brain Injury in Adolescents With Sport-Related Concussion
- Altered brain connectivity in mild cognitive impairment is linked to elevated tau and phosphorylated tau, but not to GAP-43 and Amyloid-β measurements: a resting-state fMRI study
- A prediction model of dementia conversion for mild cognitive impairment by combining plasma pTau181 and structural imaging features
- Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome
- Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome
- Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome
- Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia
- CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease
- Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts
- Hormone therapy is associated with lower Alzheimer's disease tau biomarkers in post-menopausal females -evidence from two independent cohorts
- Hormone therapy is associated with lower Alzheimer's disease tau biomarkers in post-menopausal females -evidence from two independent cohorts
- Causal association between plasma metabolites and neurodegenerative diseases
- Causal association between plasma metabolites and neurodegenerative diseases
- An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease
- Association of Seizure Control With Cognition in People With Normal Cognition and Mild Cognitive Impairment
- Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice
- Associations of cerebrovascular disease and Alzheimer's disease pathology with cognitive decline: Analysis of the National Alzheimer's Coordinating Center Uniform Data Set
- Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay
- The relationship between adult hippocampal neurogenesis and cognitive impairment in Alzheimer's disease
- Developing Topics
- (18)F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis
- Heterogeneity of cerebral atrophic rate in mild cognitive impairment and its interactive association with proteins related to microglia activity on longitudinal cognitive changes
Evidence Blueprint
Mild behavioral impairment domains are longitudinally associated with pTAU and metabolic biomarkers in dementia-free older adults
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Mild behavioral impairment domains are longitudinally associated with pTAU and metabolic biomarkers in dementia-free older adults
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Prevalence of mild behavioural impairment and its association with cognitive and functional impairment in normal cognition, mild cognitive impairment, and mild Alzheimer's dementia
- Tau-PET in early cortical Alzheimer brain regions in relation to mild behavioral impairment in older adults with either normal cognition or mild cognitive impairment
- Multimorbidity, cognitive phenotypes, and Alzheimer's disease plasma biomarkers in older adults: A population-based study
- Relationship between Loneliness and Mild Behavioral Impairment: Validation of the Japanese Version of the MBI Checklist and a Cross-Sectional Study
- Mild Behavioral Impairment and Cerebrovascular Profiles Are Associated with Early Cognitive Impairment in a Community-Based Southeast Asian Cohort
- The mind and motion: exploring the interplay between physical activity and Mild Behavioral Impairment in dementia-free older adults
- Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: The Strong Heart Study
- The effect of study partner characteristics on the reporting of neuropsychiatric symptoms across the neurocognitive spectrum
- Tau pathology mediate the plasma biomarkers and cognitive function in patients with mild cognitive impairment
- Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals
- Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study
- Diagnostic approaches to assessing mild behavioral impairment in patients with mild cognitive impairment
- Unraveling the Potential Underlying Mechanisms of Mild Behavioral Impairment: Focusing on Amyloid and Tau Pathology
- Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study
- Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort
- Association of polygenic risk scores with Alzheimer's disease and plasma biomarkers among Chinese older adults: A community-based study
- Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts
- Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings
- Assessing cognitive impairment and disability in older adults through the lens of whole brain white matter patterns
- Assessing cognitive impairment and disability in older adults through the lens of whole brain white matter patterns
- Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients
- CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease
- Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case-control study of patients with bipolar disorder and healthy control individuals
- Longitudinal assessment of plasma biomarkers for early detection of cognitive changes in subjective cognitive decline
- Biomarkers of Neurodegeneration and Alzheimer's Disease Neuropathology in Adolescents and Young Adults with Youth-Onset Type 1 or Type 2 Diabetes: A Proof-of-Concept Study
- Impact of amyloid and cardiometabolic risk factors on prognostic capacity of plasma neurofilament light chain for neurodegeneration
- Association of Plasma Markers of Alzheimer's Disease, Neurodegeneration, and Neuroinflammation with the Choroid Plexus Integrity in Aging
- Blood Pressure Variability and Plasma Biomarkers of Neuronal Injury and Alzheimer's Disease: A Clinic-Based Study of Patients with Diseases Along the Heart-Brain Axis
- Novel measures of cognition and function for the AD spectrum in the Novel Measures for Alzheimer's Disease Prevention Trials (NoMAD) project: Psychometric properties, convergent validation, and contrasts with established measures
- Entorhinal-based path integration selectively predicts midlife risk of Alzheimer's disease
- Predicting the severity of mood and neuropsychiatric symptoms from digital biomarkers using wearable physiological data and deep learning
- Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- The Alzheimer's Disease Neuroimaging Initiative Clinical Core
- Plasma Leptin and Alzheimer Protein Pathologies Among Older Adults
- Elevated plasma neurofilament light was associated with multi-modal neuroimaging features in Alzheimer's disease signature regions and predicted future tau deposition
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
- Psychosis in Alzheimer Disease and Elevations in Disease-Relevant Biomarkers
- Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population
- Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment
- APOE ε4 carrier status modifies plasma p-tau181 concentrations in cognitively healthy super-seniors
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
- Depressive Symptoms and Plasma Markers of Alzheimer's Disease and Neurodegeneration: A Coordinated Meta-Analysis of 8 Cohort Studies
- Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS)
- Empirically derived psychosocial-behavioral phenotypes in Black/African American and Hispanic/Latino older adults enrolled in HABS-HD: Associations with AD biomarkers and cognitive outcomes
- A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function
- Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly
- Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly
- Longitudinal trajectories of Alzheimer's disease CSF biomarkers and blood pressure in cognitively healthy subjects
- Identification of Neuropsychiatric Symptoms in Preclinical and Prodromal Stages in Dementias: Development of a Screening Test for Mild Behavioral Impairment
- Echocardiographic measures of the left heart and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: The CABLE study
- Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms
- Brain Age Estimation on a Dementia Cohort Using FLAIR MRI Biomarkers
- Neuropsychiatric symptoms and ApoE genotype in older adults without dementia: a cross-sectional study
- Associations between cardiometabolic multimorbidity and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study
- Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease
- Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment
- Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
- Diagnostic and predictive power of plasma proteins in Alzheimer's disease: a cross-sectional and longitudinal study in China
- Plasma BDNF/Irisin Ratio Associates with Cognitive Function in Older People
- Plasma Phosphorylated Tau 217 and Abeta42/40 to Predict Early Brain Abeta Accumulation in People Without Cognitive Impairment
- Plasma Phosphorylated Tau 217 and Abeta42/40 to Predict Early Brain Abeta Accumulation in People Without Cognitive Impairment
- Day-to-day sleep variability with Alzheimer's biomarkers in at-risk elderly
- Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network